Ypsomed and Dexcom enter into partnership to drive closed loop system.

Press Releases Ypsomed Group

Burgdorf/San Diego – Ypsomed (SWX:YPSN) and DexCom Inc. (NASDAQ:DXCM), the world's leading provider of continuous glucose monitoring (CGM) systems, announce their partnership to drive development of a hybrid closed loop system. The partnership is an important milestone in the further development of individualised diabetes therapy. In a first step, CGM data from Dexcom will be integrated into the mylife App from Ypsomed.

Teva has announced the launch of AJOVY in an autoinjector device for the German market in March 2020.
AJOVY autoinjector

Press Releases Ypsomed Group

Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including central nervous system, pain and respiratory, launches its drug product AJOVY® in the pre-filled YpsoMate 2.25 autoinjector from Ypsomed. AJOVY® is used for the preventive treatment of migraine in adults. The collaboration with Teva marks the first commercial market entry of Ypsomed’s larger 2.25 ml autoinjector YpsoMate 2.25.

Press Releases Ypsomed Group

We are monitoring the global development after the outbreak of the Coronavirus very closely. Our highest priority is our business continuity and the reliable supply of our products as well as the safety of our employees. We can confirm that to date there is no impact on the supply of our products and that our production sites are fully operational.

Press Releases Ypsomed Group

Burgdorf – Ypsomed is recording weaker growth in the insulin pump business and is adjusting its approval strategy with the American FDA. In addition, Ypsomed is reducing its EBIT outlook for the current financial year 2019/20 to CHF 9 million due to one-time and temporary effects. Ypsomed confirms its mid-term EBIT target of CHF 100 million.

Market entry of YpsoMate autoinjector for Teribone™ in Japan
Teribone™ autoinjector

Press Releases Ypsomed Group

Burgdorf – Terumo Corporation (Terumo), a leading global manufacturer and distributor of medical devices, will fill its PLAJEX™ syringe with the drug Teribone™ and assemble it with the YpsoMate prefilled autoinjector from Ypsomed. Teribone™ is a Teriparatide for the treatment of osteoporosis. The drug was developed by Asahi Kasei Pharma (AKP) and will be launched in Japan.